796 SIRT7 antagonizes TGF-β signaling and inhibits breast cancer metastasis.
https://www.nature.com/articles/s41467-017-00396-9
795 Ultrastable Near-Infrared Conjugated-Polymer Nanoparticles for Dually Photoactive Tumor Inhibition.
http://onlinelibrary.wiley.com/doi/10.1002/adma.201700487/full
794 Sequentially Responsive Shell-Stacked Nanoparticles for Deep Penetration into Solid Tumors.
http://onlinelibrary.wiley.com/doi/10.1002/adma.201701170/full
793 Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers.
http://www.nature.com/articles/s41598-017-09116-1
792 A pathology atlas of the human cancer transcriptome.
http://science.sciencemag.org/content/357/6352/eaan2507
791 An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.
http://www.nature.com/nm/journal/v23/n8/abs/nm.4369.html
790 FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer.
http://stm.sciencemag.org/content/9/401/eaam9327
789 A pan-cancer biomarker is identified that can predict successful response to cancer immunotherapy in human patients.
http://science.sciencemag.org/content/357/6349/409
788 In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.
http://www.nature.com/nature/journal/v547/n7664/full/nature23270.html
787 Genome editing abrogates angiogenesis in vivo.
https://www.nature.com/articles/s41467-017-00140-3
786 A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
http://stm.sciencemag.org/content/9/399/eaaa0984
785 Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
http://www.nature.com/nature/journal/v547/n7662/full/nature23003.html
784 An immunogenic personal neoantigen vaccine for patients with melanoma.
http://www.nature.com/nature/journal/v547/n7662/full/nature22991.html
783 Contrary to expectation, lymphatic and distant metastases often arise independently in human colorectal cancer.
http://science.sciencemag.org/content/357/6346/55
782 Identification of the cell types from which relapse arises in acute myeloid leukaemia, by following leukaemia propagation from patient-derived leukaemia samples.
http://www.nature.com/nature/journal/v547/n7661/full/nature22993.html
781 Applying a new, more sensitive single-cell transcriptomics method to diagnosis, remission and progression samples from patients with chronic myeloid leukemia reveals insight into the heterogeneity of cells that resist treatment with targeted therapy, as well as into the dynamics of disease progression and its effects on nontransformed hematopoietic stem cells.
http://www.nature.com/nm/journal/v23/n6/abs/nm.4336.html
780 Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
http://www.nature.com/nm/journal/v23/n6/abs/nm.4333.html
779 Genetically engineered ‘lymphoreporter’ mouse strains are used to track melanoma dissemination in vivo, identifying midkine as a tumour-secreted factor that acts at a distance, preparing pre-metastatic niches and serving as an indicator of poor prognosis in patients.
http://www.nature.com/nature/journal/v546/n7660/full/nature22977.html
778 Metastatic progression of colorectal cancer is modeled in mice using in vivo genome editing and transplantation of engineered organoids.
http://www.nature.com/nbt/journal/v35/n6/abs/nbt.3836.html
777 Genetically engineered colon organoids form tumors that undergo a stepwise progression toward metastatic disease after orthotopic transplantation.
http://www.nature.com/nbt/journal/v35/n6/abs/nbt.3837.html
|
